CN104136612A - 特异性结合cgrp的核酸 - Google Patents

特异性结合cgrp的核酸 Download PDF

Info

Publication number
CN104136612A
CN104136612A CN201380009019.6A CN201380009019A CN104136612A CN 104136612 A CN104136612 A CN 104136612A CN 201380009019 A CN201380009019 A CN 201380009019A CN 104136612 A CN104136612 A CN 104136612A
Authority
CN
China
Prior art keywords
nucleic acid
acid molecule
seq
cgrp
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380009019.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·舒尔兹臣
W·普尔施克
F·雅洛世
K·霍利戈
C·马什
S·克鲁斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Noxxon Pharma AG filed Critical Noxxon Pharma AG
Publication of CN104136612A publication Critical patent/CN104136612A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380009019.6A 2012-01-10 2013-01-10 特异性结合cgrp的核酸 Pending CN104136612A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2012/000089 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12000105 2012-01-10
EP12000105.2 2012-01-10
PCT/EP2013/000055 WO2013104539A1 (en) 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp

Publications (1)

Publication Number Publication Date
CN104136612A true CN104136612A (zh) 2014-11-05

Family

ID=48781062

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380009019.6A Pending CN104136612A (zh) 2012-01-10 2013-01-10 特异性结合cgrp的核酸

Country Status (14)

Country Link
US (1) US9163243B2 (enExample)
EP (1) EP2802659A1 (enExample)
JP (1) JP2015506174A (enExample)
KR (1) KR20140111704A (enExample)
CN (1) CN104136612A (enExample)
AU (1) AU2013209130A1 (enExample)
BR (1) BR112014016939A2 (enExample)
CA (1) CA2860809A1 (enExample)
HK (1) HK1198370A1 (enExample)
IL (1) IL233515A0 (enExample)
MX (1) MX2014008456A (enExample)
RU (1) RU2014132706A (enExample)
SG (1) SG11201403769YA (enExample)
WO (1) WO2013104539A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113383079A (zh) * 2018-11-12 2021-09-10 阿普塔里恩生物技术股份公司 Cxcl8结合性核酸

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2802660T3 (da) 2012-01-10 2020-05-18 Aptarion Biotech Ag Nye C5A-bindende nucleinsyrer
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6584868B2 (ja) * 2015-02-25 2019-10-02 学校法人 関西大学 ゲル素材及びその製造方法
EA201890578A1 (ru) * 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183700A1 (en) * 2002-05-06 2006-08-17 Noxxon Pharma Ag Cgrp binding nucleic acids
CN101217967A (zh) * 2005-05-04 2008-07-09 诺松制药股份公司 镜像异构体的新用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
DE69433747D1 (de) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
JP4531132B2 (ja) 1995-06-02 2010-08-25 ギリード・サイエンシズ・インコーポレーテッド 増殖因子に対する高親和性オリゴヌクレオチドリガンド
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
RU2180311C1 (ru) 2001-07-05 2002-03-10 Мешалкин Георгий Алексеевич Защитная пробка
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
US7629456B2 (en) 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
ATE441706T1 (de) 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
KR20060015505A (ko) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
JP5193468B2 (ja) 2004-02-09 2013-05-08 ノクソン・フアルマ・アクチエンゲゼルシヤフト 多糖とポリヌクレオチドの複合体を製造する方法
EP2087910B1 (en) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Polymeric prodrugs
CN101098703B (zh) 2004-11-05 2011-08-03 费城儿童医院 用于分子治疗的生物降解连接剂
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
EP2407558A1 (en) 2006-10-31 2012-01-18 Noxxon Pharma AG Methods for the detection of a single- or double-stranded nucleic acid molecule
JP5941904B2 (ja) 2010-04-21 2016-06-29 ノクソン ファーマ エージー 脂質に結合する核酸
AU2012206750A1 (en) * 2011-01-10 2013-07-18 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183700A1 (en) * 2002-05-06 2006-08-17 Noxxon Pharma Ag Cgrp binding nucleic acids
CN101217967A (zh) * 2005-05-04 2008-07-09 诺松制药股份公司 镜像异构体的新用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DENEKAS ET AL.: "Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide", 《BRITISH JOURNAL OF PHARMACOLOGY》 *
EATON ET AL.: "Post-SELEX Combinatorial Optimization of Aptamers", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
JUHL ET AL.: "Effect of two novel CGRP-binding compounds in a closed cranial window rat model", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 *
TREVINO ET AL.: "Evolution of functional nucleic acids in the presence of nonheritable backbone heterogeneity", 《PNAS》 *
VATER ET AL.: "Shot bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach:Tailored-SELEX", 《NUCLEIC ACIDS RESEARCH》 *
杨晨等: "模拟乳腺癌骨转移微环境中CGRP对成骨细胞OPG和RANKL表达影响", 《中国肿瘤生物治疗杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113383079A (zh) * 2018-11-12 2021-09-10 阿普塔里恩生物技术股份公司 Cxcl8结合性核酸
CN113383079B (zh) * 2018-11-12 2024-11-19 阿普塔里恩生物技术股份公司 Cxcl8结合性核酸

Also Published As

Publication number Publication date
KR20140111704A (ko) 2014-09-19
WO2013104539A1 (en) 2013-07-18
EP2802659A1 (en) 2014-11-19
US20150031755A1 (en) 2015-01-29
AU2013209130A1 (en) 2014-07-10
CA2860809A1 (en) 2013-07-18
SG11201403769YA (en) 2014-07-30
JP2015506174A (ja) 2015-03-02
BR112014016939A2 (pt) 2019-09-24
HK1198370A1 (en) 2015-04-10
MX2014008456A (es) 2014-11-25
US9163243B2 (en) 2015-10-20
RU2014132706A (ru) 2016-02-27
IL233515A0 (en) 2014-08-31

Similar Documents

Publication Publication Date Title
CN104136612A (zh) 特异性结合cgrp的核酸
JP5308813B2 (ja) グレリン結合核酸
CN103946381B (zh) Ngf适体及其应用
US9976145B2 (en) Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
US20150232852A1 (en) Glucagon Binding Nucleic Acids
EP3065744B1 (en) A ccl2 antagonist for use in treating proteinuria
AU2005311497B2 (en) Vasopressin-binding l-nucleic acid
WO2012025251A1 (en) Nucleic acids for treatment of chronic complications of diabetes
HK1117567A (en) Ghrelin binding nucleic acids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141105